PD-1 says goodbye, TIM-3 says hello

D Romero - Nature Reviews Clinical Oncology, 2016 - nature.com
D Romero
Nature Reviews Clinical Oncology, 2016nature.com
Immune-checkpoint inhibitors, notably antibodies targeting the PD-1/PD-L1 axis, have
demonstrated efficacy as therapeutic agents for several tumour types. As Peter Hammerman
explains, however,“little is known about which patients are likely to respond to these agents
and, if they respond, the possible mechanisms of resistance to therapy are unknown.”
Findings now published by Hammerman and colleagues show that TIM-3 and other immune
checkpoints are upregulated as a result of adaptative resistance.
Immune-checkpoint inhibitors, notably antibodies targeting the PD-1/PD-L1 axis, have demonstrated efficacy as therapeutic agents for several tumour types. As Peter Hammerman explains, however,“little is known about which patients are likely to respond to these agents and, if they respond, the possible mechanisms of resistance to therapy are unknown.” Findings now published by Hammerman and colleagues show that TIM-3 and other immune checkpoints are upregulated as a result of adaptative resistance.
nature.com